Log In
BCIQ
Print this Print this
 

CKD-942

  Manage Alerts
Collapse Summary General Information
Company Chong Kun Dang Pharmaceutical Corp.
DescriptionNot disclosed
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic
Latest Stage of DevelopmentPhase II
Standard IndicationPulmonary fibrosis
Indication DetailsTreat idiopathic pulmonary fibrosis (IPF)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today